Pain Control Options for Chronic Pain When Opioids Cannot Be Used
For patients with chronic pain who cannot take opioids, nonpharmacologic therapies combined with nonopioid medications—specifically NSAIDs, acetaminophen, SNRIs (duloxetine), and anticonvulsants (gabapentin, pregabalin)—should be the primary treatment approach, with the specific regimen tailored to whether the pain is neuropathic or nociceptive in origin. 1
Treatment Algorithm Based on Pain Type
For Neuropathic Pain (diabetic neuropathy, postherpetic neuralgia, radiculopathy)
First-line pharmacologic options:
- Duloxetine (SNRI): 30-60 mg daily, titrated based on response 2, 3
- Gabapentin: Starting 300 mg daily, titrated up to 1800-3600 mg/day in divided doses 2, 4
- Pregabalin: 150-600 mg/day in divided doses 2, 4
- Tricyclic antidepressants (TCAs): Amitriptyline or nortriptyline 10-75 mg at bedtime (use caution in elderly due to cardiovascular side effects and fall risk) 3, 4
- Topical lidocaine: For localized peripheral neuropathic pain 3, 4
Recent meta-analysis data show duloxetine and mirogabalin demonstrate significant short-term efficacy specifically for fibromyalgia (SMD -2.42 and -2.10 respectively), though effectiveness for other neuropathic pain conditions was less consistent 5. The number needed to treat (NNT) for SNRIs and calcium channel blockers in neuropathic pain is 6-7, meaning 5-6 patients will receive less benefit for every one achieving >30% pain relief 2.
For Nociceptive Pain (osteoarthritis, musculoskeletal pain, low back pain)
First-line pharmacologic options:
- Acetaminophen: Up to 4 g/day (reduce dose in liver disease) 6, 3
- NSAIDs: Ibuprofen 400-800 mg TID or naproxen 500 mg BID 6, 3
- Topical NSAIDs: Preferred over oral NSAIDs for localized osteoarthritis in patients ≥75 years or those with cardiovascular/renal risk factors 3
- Tramadol: 37.5-400 mg/day in divided doses for osteoarthritis (note: tramadol has weak opioid properties but may be tolerated when traditional opioids are not) 6
Critical caveat: NSAIDs require careful risk-benefit assessment in patients with hypertension, renal insufficiency, heart failure, peptic ulcer disease risk, or cardiovascular disease. COX-2 inhibitors reduce GI complications but increase cardiovascular risk 6, 7.
Essential Nonpharmacologic Therapies (Must Be Incorporated)
These are not optional adjuncts but core components of treatment 1:
- Exercise therapy: Structured physical activity programs
- Cognitive behavioral therapy (CBT): Addresses pain catastrophizing and maladaptive coping
- Physical therapy: Addresses biomechanical contributors, muscle weakness, posture
- Biofeedback and relaxation training: Evidence supports use for back pain and other chronic conditions 4
The 2016 CDC guidelines explicitly state that nonpharmacologic and nonopioid pharmacologic therapies are preferred for chronic pain, not merely alternatives 1. This represents a fundamental shift in pain management philosophy.
Specific Clinical Scenarios
Fibromyalgia
- Duloxetine 60 mg daily (strongest evidence) 5
- Pregabalin 300-450 mg/day 2
- Milnacipran (SNRI) 2
- Avoid opioids—evidence shows they are unlikely to provide benefit and may worsen outcomes 1, 3
Low Back Pain
- Acetaminophen and NSAIDs as first-line 6
- Physical therapy and exercise (high-quality evidence for 4 weeks to 2 years of benefit) 4
- Consider epidural blockade for radicular symptoms (high-quality evidence) 2
- Evidence for long-term opioid benefit is inconclusive; avoid as first-line 2, 3
Headache
Opioids are specifically contraindicated—expected benefits unlikely to outweigh risks regardless of other therapies tried 1, 3
Monitoring and Safety Considerations
Before initiating any medication:
- Assess fall risk when prescribing sedating medications (TCAs, anticonvulsants) 3
- Evaluate cardiovascular, renal, and GI risk factors before NSAIDs 3
- Consider drug interactions, particularly in patients on multiple medications
- Establish realistic treatment goals focusing on function improvement, not just pain scores 1
Ongoing assessment:
- Reevaluate effectiveness within 1-4 weeks of starting therapy 8
- Continue therapy only if clinically meaningful improvement in both pain AND function 1
- Monitor for adverse effects specific to medication class
Common Pitfalls to Avoid
Sequential failure requirement: Patients do NOT need to "fail" each therapy sequentially before trying another. The clinical context should guide initial selection 1.
Monotherapy approach: Multimodal therapy combining pharmacologic and nonpharmacologic treatments provides superior outcomes to single-modality treatment 3, 4.
Ignoring pain mechanism: Prescribing NSAIDs for neuropathic pain or anticonvulsants for pure nociceptive pain reduces effectiveness. Match medication class to pain type 3.
Overlooking topical agents: For localized pain (peripheral neuropathy, localized osteoarthritis), topical lidocaine or NSAIDs avoid systemic side effects 3, 4.
Underutilizing nonpharmacologic therapies: These are not "alternatives" but core treatments that should be initiated concurrently with medications 1.
Special Populations
Elderly patients (≥75 years):
- Prefer topical NSAIDs over oral for localized osteoarthritis 3
- Use lower doses of TCAs due to anticholinergic effects and fall risk 3
- Increased caution with all sedating medications 3
Patients with comorbidities:
- Cardiovascular disease: Avoid NSAIDs or use lowest effective dose for shortest duration 3
- Renal insufficiency: Avoid or carefully dose-adjust NSAIDs 3
- Liver disease: Reduce acetaminophen dose below 4 g/day 6
- Depression/anxiety: SNRIs (duloxetine) address both pain and psychiatric comorbidity 2
When to Consider Pain Specialty Referral
Refer for complex pain syndromes when:
- Initial multimodal therapy fails to provide meaningful improvement
- Diagnostic uncertainty exists
- Interventional procedures may be beneficial (e.g., nerve blocks, epidural injections) 3
- Severe functional impairment despite treatment
The evidence consistently demonstrates that while no single therapy provides complete pain relief for most patients, a structured multimodal approach combining mechanism-specific medications with active nonpharmacologic therapies offers the best outcomes for chronic pain management without opioids 1, 4.